Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that reduces prostaglandin synthesis, thereby decreasing inflammatory responses and pain signaling. In cluster headache management, it acts to mitigate neurogenic inflammation and provide analgesic effects by selectively blocking COX-2 enzymes, potentially interrupting the pain cascade associated with these severe headaches.